Canadian Integrated Program for Antimicrobial Resistance Surveillance (CIPARS)

First Page		Document Content
Date: 2014-07-31 14:32:06 Eli Lilly and Company Antimicrobial Microbiology Defined daily dose Pharmacy Vancomycin Antibiotic resistance Drug resistance Pefloxacin Medicine Chemistry Health		Canadian Integrated Program for Antimicrobial Resistance Surveillance (CIPARS) Add to Reading List Source URL: publications.gc.ca Download Document from Source Website File Size: 1,61 MB Share Document on Facebook

	Joint Statement on Antimicrobial Resistance Executive Summary Antimicrobial resistance, also known as AMR, is a major public health threat. The estimated burden of deaths from drug resistant infections is calc DocID: 1uNZ0 - View Document
	TACKLING DRUG-RESISTANT INFECTIONS GLOBALLY: FINAL REPORT AND RECOMMENDATIONS THE REVIEW ON ANTIMICROBIAL RESISTANCE DocID: 1tod4 - View Document
	Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding Keith P. Romano1, Akbar Ali1, William E. Royer, and Celia A. Schiffer2 Department of Biochemistry DocID: 1tlKl - View Document
	WHO/TDR TB Strain Bank New diagnostics tests for tuberculosis (TB) suitable for low-income settings are urgently needed. This includes tests for the detection of drug resistance which are of ever increasing importance as DocID: 1t8wk - View Document
	Texas A&M AgriLife ResearchSELECTED ACCOMPLISHMENTS Combating Drug Resistance DocID: 1slem - View Document